UCB U.S. News

UCB's Global Corporate Website

Welcome to UCB in the United States

14 UCB Announces U.S. Availability of BIMZELX® for the Treatment of Adults with Moderate-to-Severe Plaque Psoriasis

Read More Share:

Oct

18 BIMZELX® Approved by the U.S. FDA for the Treatment of Adults with Moderate-to-Severe Plaque Psoriasis

Read More Share:

Aug

01 Evolving Expectations for Dermatological Conditions

Read More Share:

Feb

10 Partnering With the Dermatology Community to Improve Health Equity

Read More Share:

Dec

23 UCB Announces FDA Acceptance of BLA Resubmission for Bimekizumab

Read More Share:

Dec

07 The Lancet Publishes Results from Two Bimekizumab Phase 3 Studies in Psoriatic Arthritis

Read More Share:

Nov

22 UCB Submits Response to FDA Complete Response Letter for Bimekizumab

Read More Share:

Oct

10 Using Data and Technology to Enable Better Patient Care

UCB has been rapidly investing in our digital business transformation to unleash the power of digital innovation to help achieve better outcomes for patients, faster.

Read More Share:

Sep

07 New Three-Year Bimekizumab Data Reinforce Long-Term Maintenance of Complete Skin Clearance in Moderate to Severe Plaque Psoriasis

Read More Share:

Sep

01 UCB Showcases Strength of the Expanding Dermatology Portfolio at the 31st EADV Congress

Read More Share:

Categories

Archives

Nov

14

UCB Announces U.S. Availability of BIMZELX® for the Treatment of Adults with Moderate-to-Severe Plaque Psoriasis

Oct

18

BIMZELX® Approved by the U.S. FDA for the Treatment of Adults with Moderate-to-Severe Plaque Psoriasis

Aug

01

Evolving Expectations for Dermatological Conditions

Feb

10

Partnering With the Dermatology Community to Improve Health Equity

Dec

23

UCB Announces FDA Acceptance of BLA Resubmission for Bimekizumab

Dec

07

The Lancet Publishes Results from Two Bimekizumab Phase 3 Studies in Psoriatic Arthritis

Nov

22

UCB Submits Response to FDA Complete Response Letter for Bimekizumab

Oct

10

Using Data and Technology to Enable Better Patient Care

Sep

07

New Three-Year Bimekizumab Data Reinforce Long-Term Maintenance of Complete Skin Clearance in Moderate to Severe Plaque Psoriasis

Sep

01

UCB Showcases Strength of the Expanding Dermatology Portfolio at the 31st EADV Congress

Choose Country

UCB in the U.S.

Patients

Innovation

Sustainability

Newsroom

Contact

Notice about cookies

Categories

Archives

Nov

14

UCB Announces U.S. Availability of BIMZELX® for the Treatment of Adults with Moderate-to-Severe Plaque Psoriasis

Oct

18

BIMZELX® Approved by the U.S. FDA for the Treatment of Adults with Moderate-to-Severe Plaque Psoriasis

Aug

01

Evolving Expectations for Dermatological Conditions

Feb

10

Partnering With the Dermatology Community to Improve Health Equity

Dec

23

UCB Announces FDA Acceptance of BLA Resubmission for Bimekizumab

Dec

07

The Lancet Publishes Results from Two Bimekizumab Phase 3 Studies in Psoriatic Arthritis

Nov

22

UCB Submits Response to FDA Complete Response Letter for Bimekizumab

Oct

10

Using Data and Technology to Enable Better Patient Care

Sep

07

New Three-Year Bimekizumab Data Reinforce Long-Term Maintenance of Complete Skin Clearance in Moderate to Severe Plaque Psoriasis

Sep

01

UCB Showcases Strength of the Expanding Dermatology Portfolio at the 31st EADV Congress

Choose Country

UCB in the U.S.

Patients

Innovation

UCB Worldwide

Sustainability

Newsroom

Contact